Zerion, Inc.

May 13, 2024 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces positive results from the first human clinical study of a Dispersome® formulation of the drug Ivacaftor, a pharmaceutical used to treat cystic fibrosis. The study was conducted by ZERION’s Spanish partner Insud Pharma, a global leader in generic and branded pharmaceuticals. The clinical study was a comparative oral bioavailability pilot study designed to assess the pharmacokinetic parameters of two different Ivacaftor Dispersome® formulations relative to the approved product Kalydeco® 150 mg film-coated tablets (Ivacaftor). Ivacaftor is formulated as a polymeric amorphous solid dispersion in Kalydeco®. The study was conducted as a crossover study with the participation of 18 subjects (healthy volunteers). One of the Ivacaftor Dispersome® formulations showed improved bioavailability compared to the reference product, while the pharmacokinetic parameters for the second formulation were equivalent to Kalydeco®. Both Ivacaftor Dispersome® formulations carried high content (drug load) of Ivacaftor and were designed to increase the solubility of this poorly soluble compound. “We are extremely pleased with the results of this study that mark the conclusion of years of efforts to demonstrate the benefit of our Dispersome® technology for patients. The study results are just spot on and confirm the good performance that we had predicted from in-vitro studies in our laboratory as well as multiple animal studies on many other drugs. The results represent the biggest milestone for ZERION so far, and prove that Dispersome® will bring benefits to patients in the form of completely new or better drug products”, says Ole Wiborg, CEO of ZERION, adding: ”Without the efforts of our partner Insud Pharma, we would not have accomplished this. Thus, we are truly grateful to Insud Pharma that early on showed trust in our technology and has been performing excellent in their planning and carrying out the clinical study”. ZERION announced its collaboration with Insud Pharma in August 2022. The Ivacaftor Dispersome® product is the first product originating from the collaboration that has been investigated in a human clinical trial. Ivacaftor is used to treat cystic fibrosis in patients with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is also used in combination with other drugs such as tezacaftor and elexacaftor to treat people with cystic fibrosis. About Zerion Pharma A/S ZERION develops its own proprietary drug formulations and offers its Dispersome® technology platform to established pharma companies as a means to solve their challenging drug solubility problems. By applying ZERION’s technology, the solubility of poorly soluble compounds may be greatly enhanced, which improves their oral bioavailability and thereby therapeutic outcomes for the patients. ZERION was established in 2019 as a spin-out from the University of Copenhagen based on almost a decade of research. About Insud Pharma Insud Pharma operates throughout the entire pharmaceutical value chain, delivering specialist expertise in scientific research, development, manufacturing, sales and marketing for a wide range of active pharmaceutical ingredients (APls), finished dosage forms (FDFs), branded pharmaceuticals for human and animal care and biopharmaceutical products to treat and prevent diseases across different therapeutic areas. With over 45 years' experience, Insud Pharma is well-positioned in the global pharmaceutical sector and is committed to continuous growth and diversification. Insud Pharma is present at every level of the chemical and pharmaceutical industry through its business units including, among others, Chemo, Exeltis and Xiromed. Insud Pharma has 9,000 employees and operates in more than 50 countries. For more information, please visit or contact: Ole Wiborg, CEO Mobile: +45 40 96 80 18 E-mail: info@zerion.eu Follow us on: LinkedIn

First Cannabidiol drug formulation from partnership to enter clinical studies in 2024 February 15, 2024 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces an exclusive partnership with dsm-firmenich to take advantage of ZERION’s expertise and its Dispersome® technology for improving the bioavailability of cannabinoids. Improvements in bioavailability of cannabinoids can open the way for broadly applying these compounds for medical and nutritional purposes via the oral route. dsm-firmenich and ZERION have worked together since 2022 to develop improved cannabinoid products of high quality that can provide meaningful and proven health benefits to patients with various diseases. The collaboration has now resulted in formulations of Cannabidiol (CBD) with improved solubility and bioavailability compared to the crystalline material, and which are expected to match or surpass existing formulations of CBD. The quality and characteristics of the new CBD formulations make them candidates to become best-in-class materials in a variety of indications where CBD is thought to have a positive effect, such as severe pain, inflammation disorders, depression, and anxiety. dsm-firmenich is planning to conduct a clinical pharmacokinetic evaluation of the improved CBD formulations in 2024. Upon successful completion of the clinical study, the new CBD Dispersome® intermediate product will be made available to the global pharmaceutical industry engaged in developing effective CBD containing drug products under partnerships with dsm-firmenich. “We are extremely happy to have partnered with dsm-firmenich that we consider a global leader in the development of novel and improved cannabinoid products. We are therefore proud to announce this partnership that has already resulted in formulations with significant improvement in CBD solubility. To me, this is a clear recognition and evidence of ZERION’s formulation expertise and the game-changing potential of our technology platform”, says Ole Wiborg, CEO of ZERION. About Zerion Pharma A/S ZERION develops its own proprietary drug formulations and offers its Dispersome® technology platform to established pharma companies as a means to solve their challenging drug solubility problems. By applying ZERION’s technology, the solubility of poorly soluble compounds may be greatly enhanced, which improves their oral bioavailability and thereby therapeutic outcomes for the patients. ZERION was established in 2019 as a spin-out from the University of Copenhagen based on almost a decade of research. About dsm-firmenich As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life™ every day, everywhere, for billions of people. For more information, please visit or contact: Ole Wiborg, CEO Mobile: +45 40 96 80 18 E-mail: info@zerion.eu Follow us on: LinkedIn

COPENHAGEN, Denmark, Sept. 25, 2023 /PRNewswire/ -- Zerion Pharma A/S ("ZERION") today announces that the Company has elected Mr. Carl-Åke Carlsson as its new Chairman of the Board of Directors. Mr. Carlsson brings over three decades of leadership and strategic experience in the pharmaceutical industry and embodies Scandinavian diversity: Born in Norway with Swedish ancestry and having spent over a decade living and working in Denmark. Carl-Åke joins Zerion's Board after 15 years as CEO of Xellia Pharmaceuticals, specializing in anti-infective and critical care treatments. Under his leadership, Xellia transitioned from a Scandinavian entity to a global contender, boasting annual sales to USD 300 million and a robust team of around 1,800 employees. "We are excited to welcome Mr. Carlsson to our leadership team," said Ole Wiborg, CEO of ZERION, and continues: "ZERION stands in front of significant opportunities on the path to commercialise our Dispersome® technology platform, and I am convinced that Mr. Carlsson will be able to make a great contribution in both setting and implementing the strategic direction to exploit these opportunities to their maximum." For his part, Mr. Carlsson commented, "I'm excited to join ZERION in this important role. I believe the company's technology holds immense potential, and I'm eager to contribute to the company's growth and innovation." ZERION's Dispersome® technology has proven to be very efficient in improving the solubility and bioavailability of small molecule drugs. ZERION has established partnerships with a significant number of large pharmaceutical companies that are exploiting the Dispersome® platform for both new chemical entities as well as currently marketed drugs. Some of these partnerships are now proceeding into the clinical phase. Before his tenure at Xellia, Mr. Carlsson held several leadership roles at Alpharma (NYSE:ALO). For a decade, he was integral to the top leadership, overseeing business within pharmaceutical retail, specialty institutional markets, and the extensive global B2B sectors. Mr. Carlsson is also serving at prominent board positions, including the biotech company Vectron Biosolutions and Lecka Alpha Trading LP. About Zerion Pharma A/S ZERION develops its own proprietary drug formulations and offers its Dispersome® technology platform to established pharma companies as a means to solve their challenging drug solubility problems. By applying ZERION's technology, the solubility of poorly soluble compounds may be greatly enhanced, which improves their oral bioavailability and thereby therapeutic outcomes for the patients. ZERION was established in 2019 as a spin-out from the University of Copenhagen based on almost a decade of research. For more information, please visit or contact: Ole Wiborg, CEO, Mobile: +45 40 96 80 18, E-mail: [email protected] The following files are available for download: SOURCE Zerion Pharma A/S